NeoStem to Present at Multiple September Conferences in 2013

Caladrius Biosciences, Inc. - $CLBS |

New York, September 3, 2013 — NeoStem, Inc. (Nasdaq: NBS) (“NeoStem” or the “Company”), a leader in the emerging cellular therapy market, announced today that the Company and its subsidiary, Progenitor Cell Therapy (“PCT”), will present at multiple upcoming conferences in September.

European Society of Cardiology Congress: Acute Cardiac Care 2013

Rodman & Renshaw 15th Annual Healthcare Conference

International Society for Cellular Therapy (ISCT) North American Regional Meeting 2013

Stifel Annual Healthcare Conference 2013

Heart Failure Society of America 17th Annual Scientific Meeting

Aegis Capital Corp. 2013 Healthcare Conference

BioCentury Newsmakers in the Biotech Industry

The Symposium on Advanced Wound Care

Stem Cells & Regenerative Medicine Congress

About NeoStem

NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not necessarily represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Market Movers

Sponsored Financial Content